CIBUS INC
CBUSNASDAQ🏆 #3931 by market capEarnings Nov 5US Equity
$1.37▼ $0.04 (−2.84%)
Latest quoteTrack CBUS
Get earnings, price moves & breaking news on Telegram
24h▼ 2.8%
7d▼ 3.5%
14d▲ 7.0%
30d▼ 12.2%
ytd▼ 20.6%
1y▼ 13.0%
🏦Market Cap
$105M
Small Cap
📈Revenue Growth (YoY)
-10.3%
Declining
📊Gross Margin
100.0%
High
💵FCF Margin
—
⚖️P/S Ratio
24.8x
Expensive
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $1.37 – $1.42
- 52-Week Range
- $1.09 – $4.19
- Volume (shares)
- 1,966
- Avg Volume (shares)
- —
- Shares Outstanding
- 76.4M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 24.8x
- EPS (TTM)
- $-1.65
- Dividend Yield
- —
CIBUS INC
CBUSFinancial Trends
Financial history unavailable.
StockOtter · stockotter.spaceAbout CIBUS INC
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
9 analysts
Strong Buy2
Buy5
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.